I-NCT03142334, I-Pembrolizumab, i-renal cell carcinoma

I-Pembrolizumab ivunyelwe ukwelashwa kwe-adjuvant ye-renal cell carcinoma

Jan 2022: I-Pembrolizumab (Keytruda, Merck) igunyazwe yi-Food and Drug Administration yokwelashwa kwe-adjuvant yeziguli ezine-renal cell carcinoma (RCC) ezisengozini emaphakathi noma ephezulu yokuphinda iphindeke ngemuva ...

KEYTRUDA, I-Lenvatinib, I-Lenvatinib kanye ne-pembrolizumab, Lenvima, Merck, i-renal cell carcinoma

I-FDA igunyaze ukuhlanganiswa kwe-lenvatinib ne-pembrolizumab ye-renal cell carcinoma ethuthukile

Agasti 2021: Inhlanganisela yelenvatinib (Lenvima, Eisai) kanye ne pembrolizumab (Keytruda, Merck) ivunyelwe yi-Food and Drug Administration ekwelashweni kolayini wokuqala kweziguli ezindala ezine-renal cell carcinom ..

I-AVEO Imithi, I-Fotivda, i-kinase inhibitor, i-refractory advanced renal cell carcinoma, i-renal cell carcinoma, tivozanib

I-Tivozanib ivunyelwe yi-FDA yokwelashwa kwe-renal cell carcinoma ebuyile noma ephikisayo.

Agasti 2021: I-Tivozanib (i-Fotivda, i-AVEO Pharmaceuticals, Inc.), i-kinase inhibitor, ivunyelwe yi-FDA yeziguli ezindala ezine-renal cell carcinoma (RCC) ebuyela emuva noma ephikisayo ngemuva kwezinhlelo ezimbili noma ngaphezulu ezedlule ..

Izimbangela eziyisi-8 zomdlavuza wezinso

Many patients with kidney cancer do not know why they have this disease, meaning the causes of kidney cancer are relatively unknown. After the examination, they will be very surprised. Some even feel that the kidney is not a probl..